drugset / Trial / NCT00052130

Vaccine Therapy for Patients With Stage III Melanoma

NCT00052130 ↗

Phase 3 Unknown 1118 enrolled CancerVax Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject CancerVax Vaccine — —

Indications